Author:
Thoss K.,Henzgen S.,Petrow P. K.,Katenkamp D.,Bräuer R.
Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Bartlett RR, Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol 1985;7:7–18.
2. Pasternak RD, Wadopian NS, Wright RN, Siminoff P, Gylys JA, Buyniski JP. Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis. Agents Actions 1987;21:241–3.
3. Hambleton P, McMahon S. Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis. Agents Actions 1990;29:328–32.
4. Glant TT, Mikecz K, Bartlett RR, Deak F, Thonar EJMA, Williams JM, et al. Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide. Immunopharmacology 1992;23:105–16.
5. Seifert H, Misikic P, Oed C, Löw-Friedrich I, Campion G. Clinical experience with leflunomide in patients with rheumatoid arthritis (RA). In: Bartlett RR, editor. Leflunomide. Proc Vienna Symp. Basel: Birkhäuser, 1993: p A5.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献